- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00971347
Chewing Gum for Weight Loss
November 22, 2010 updated by: University of Alabama at Birmingham
Randomized Controlled Trial of Chewing Gum for Weight Loss
This is a randomized controlled trial of the effects of chewing gum on body weight.
The investigators will randomly assign 200 overweight or mildly obese adults to one of two groups.
Participants must be otherwise healthy and ages 19-50.
The control group will receive only printed information on optimal diet and increasing physical activity.
The intervention group will be instructed to chew gum following meals and in place of snacks for a minimum of 90 minutes per day.
The intervention group also will receive the same information on optimal diet and increasing physical activity as the control group.
In this 8-week intervention, the primary outcome will be change in body weight, and secondary outcomes will be changes in body mass income (BMI), waist circumference, and blood pressure.
The protocol includes 3 clinic visits to assess outcomes: baseline, 4 weeks after randomization, and 8 weeks after randomization.
Adherence to the gum chewing protocol will be assessed at clinic visits and during 2 telephone calls at 2 weeks and 6 weeks post-randomization.
The investigators' hypothesis is that gum-chewers will lose more weight than those who receive information only.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
In this randomized controlled trial of the effects of chewing gum on body weight, we will randomly assign 200 overweight or mildly obese, but otherwise healthy adults (men and women, ages 19 to 50), to one of two groups: 1) a control group, which will receive printed information on optimal diet and increasing physical activity only, or 2) an intervention group, in which participants will be instructed to chew gum following meals and in place of snacks for a minimum of 90 minutes per day, in addition to receiving the same information on optimal diet and increasing physical activity as the control group.
In this 8-week intervention, the primary outcome will be change in body weight, and secondary outcomes will be changes in body mass income (BMI), waist circumference, and blood pressure.
Outcome measures will be assessed in both groups via clinic visits at baseline, 4 weeks post-randomization, and 8 weeks post-randomization.
Adherence to the gum chewing protocol will be assessed at the clinic visits, as well as during telephone contacts at 2 weeks and 6 weeks post-randomization.
The effects of the chewing gum intervention will be assessed by analysis of covariance (ANCOVA), wherein treatment assignment is the independent variable; the outcome measures described above will serve as dependent variables; and pre-randomization factors such as age, sex, and baseline BMI will be used as covariates.
Our hypothesis is that those randomized to the intervention group will lowe more weight than those randomized to the control group.
Study Type
Interventional
Enrollment (Anticipated)
200
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Alabama
-
Birmingham, Alabama, United States, 35205
- University of Alabama at Birmingham Division of Preventive Medicine
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
19 years to 50 years (Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- 19 - 50 years of age
- BMI 25 - 35 kg/m2
- Non-diabetic; no previous history of diabetes
- Fasting glucose <126 mg/dL at recruitment
- Male or female
- Any race or ethnicity
Exclusion Criteria:
- Any major disease including:
- Active cancer or cancer requiring treatment < 2 years (except nonmelanoma skin cancer).
- Active or chronic infections including self-reported HIV and active tuberculosis.
- Active cardiovascular disease or event with hospitalization; or therapeutic procedures for treatment of heart disease <6 months; or New York Heart Association Functional Class >2 for congestive heart failure, stroke or transient ischemic attack < 6 months.
- Uncontrolled hypertension: ≥SBP 160 mm Hg or DBP ≥95 mm Hg on treatment.
- GI disease: self-reported chronic hepatitis or cirrhosis; alcoholic hepatitis or alcoholic pancreatitis < 12 months; inflammatory bowel disease treatment < 12 months; recent or significant abdominal surgery.
- Renal disease: serum creatinine ≥1.4 mg/dL (124 μmol/L) for men; ≥1.3 mg/dL (115 μmol/L) for women.
- Lung disease: chronic obstructive airway disease with use of oxygen.
- Diagnosed diabetes (type 1 or 2), fasting hyperglycemia (blood glucose ≥ 126 mg/dL), or use of any anti-diabetic medications.
- Uncompensated or uncontrolled psychiatric disease that would impede conduct of the trial or completion of procedures.
- Phenylketonuria.
- Temporomandibular joint disorders.
- < 16 natural, fully crowned, or restored teeth in a good state of repair.
- Inadequate oral hygiene.
- Sensitivity to flavors, sweeteners, or other ingredients in sugar-free chewing gum.
- Refusal to chew gum per study guidelines.
- Currently chewing ≥5 sticks of gum per week.
- Weight loss or gain of >10% in the past 6 months except post-partum weight loss.
- Current participation in any weight-reduction program.
- Current smoker or quit < 6 months.
- History of prior surgical procedure for weight control or liposuction.
- Unable or unwilling to give informed consent; unable to communicate with clinic staff; another household member is a participant or staff member in the trial; unwilling to accept randomization; current or anticipated participation in another intervention research project that would interfere with the intervention offered in the trial; likely to move away before trial completed; unable to walk 0.25 mile in 10 minutes.
- Currently pregnant or < 3 months post partum; currently nursing or within 6 weeks of having completed nursing; pregnancy anticipated during study; unwilling to report possible or confirmed pregnancies promptly during the trial; unwilling to take adequate contraceptive measures if potentially fertile.
- Brief Symptom Inventory score (Derogatis & Melisaratos, 1983) > 90th percentile.
- Any active use of illegal or illicit drugs or history of such use < 12 months. Excessive alcohol intake, acute or chronic: average consumption of 3+ alcohol containing beverages daily; consumption of 7+ alcoholic beverages within a 24-hr period <12 months; or other evidence available to clinic staff. Subject may still be considered eligible if, upon explanation, the clinic staff believe that the volunteer can and will limit future intake.
- This is a partial listing; complete list available from PIs.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Active Comparator: Nutrition brochure
Control participants will receive only a nutrition brochure, Finding Your Way to a Healthier You, based on a USDHHS/USDA publication, Dietary Guidelines for Americans 2005.
|
one-time at baseline visit
Other Names:
|
|
Experimental: Chewing gum + nutrition brochure
Participants in the experimental arm will be instructed to incorporate gum chewing in their diet with a goal of at least 90 minutes per day.
The schedule is 20 minutes each after breakfast, lunch and dinner plus 10 minutes mid-morning, mid-afternoon and 1 to 2 hours after dinner.
Experimental participants also will be told to chew gum instead of unplanned eating in response to hunger, cravings, preoccupation with eating, or negative feelings.
|
one-time at baseline visit
Other Names:
90 minutes chewing per day after meals; mid-morning and mid-afternoon; 1 to 2 hours after dinner; and in response to hunger, cravings, preoccupation with eating, or negative feelings in general throughout the day.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
weight change in kg
Time Frame: 8 weeks
|
8 weeks
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Body mass index in kilograms per meter-squared
Time Frame: 8 weeks
|
8 weeks
|
|
waist circumference in cm
Time Frame: 8 weeks
|
8 weeks
|
|
blood pressure in mm of mercury
Time Frame: 8 weeks
|
8 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Investigators
- Principal Investigator: James M. Shikany, DrPH, University of Alabama at Birmingham
- Principal Investigator: David B. Allison, PhD, University of Alabama at Birmingham
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
August 1, 2009
Primary Completion (Actual)
June 1, 2010
Study Completion (Actual)
June 1, 2010
Study Registration Dates
First Submitted
September 2, 2009
First Submitted That Met QC Criteria
September 2, 2009
First Posted (Estimate)
September 3, 2009
Study Record Updates
Last Update Posted (Estimate)
November 23, 2010
Last Update Submitted That Met QC Criteria
November 22, 2010
Last Verified
November 1, 2010
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 000354619
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.